Dr Mikael Sodergren

Dr Mikael Sodergren is Senior Clinical Lecturer at Imperial College London and Consultant Hepatobiliary & Pancreatic Surgeon at Imperial College Healthcare NHS Trust. He is also the Chief Medical Officer of Curaleaf International, where he leads the clinical and pre-clinical cannabinoid research programme. Dr Sodergren specialises in complex pancreas, liver and gallbladder surgeries including keyhole and robotic surgeries. Dr Sodergren has published over 150 peer-reviewed articles, in addition to several book chapters and he is on the editorial board of 3 medical journals. He has a diverse portfolio of research and is the inventor of an internationally patented surgical device. He leads the Medical Cannabis Research Group – a research programme which evaluates and develops novel therapies targeting the endocannabinoid system through a framework of in vitro, in vivo, and clinical translational activities.

Dr Mikael Sodergren has also written in:

Education:

MBChB (Batchelor of Medicine, Batchelor of Surgery), DIC (Diploma of Imperial College), PhD (Doctor of Philosophy, Imperial College London), FRCS (Fellowship of the Royal College of Surgeons of England). He previously held the prestigious NIHR TCC Academic Clinical Lectureship in Surgery at Imperial College.

Credentials:

He spearheaded the team that pioneered and carried out the first cases of natural orifice translumenal endoscopic surgery (NOTES) in the UK. Mikael also leads the Imperial College Medical Cannabis Research Group.

Awards:

In addition to over 15 medical awards such as the High Atlimetric Score from the British Journal of Surgery, specifically related to medical cannabis he has been awarded the Canex 2021 ‘Bringing Treatment to the Masses’ award for the Sapphire Access Scheme, the Cannabis Scientist 2022 Power List ‘Inspirational Mentor’, and the Cannavist Most Influential People in CBD & Medical Cannabis 2020

Previous Experience:

His research portfolio focuses on a range of key areas of innovation in medicine and surgery, including immunomodulatory cancer therapies, medical cannabis, the advancement of surgical devices, and medical eye tracking.

top articles by Dr Mikael Sodergren

Sapphire’s Access Scheme continues to expand and offer another 2,000 patients access to medical cannabis consultations

4th November 2022

A Review of the Evidence for Medical Cannabis and Multiple Sclerosis 

26th August 2022

Our latest research on medical cannabis for chronic pain

5th April 2022

One Year On: Access to medical cannabis for patients in Scotland

22nd March 2022

Scotland’s first medical cannabis clinic registered with Healthcare Improvement Scotland receives rating

16th February 2022

other authors